1. Home
  2. ALT vs GAU Comparison

ALT vs GAU Comparison

Compare ALT & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • GAU
  • Stock Information
  • Founded
  • ALT 1997
  • GAU 1999
  • Country
  • ALT United States
  • GAU Canada
  • Employees
  • ALT N/A
  • GAU N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • GAU
  • Sector
  • ALT Health Care
  • GAU
  • Exchange
  • ALT Nasdaq
  • GAU Nasdaq
  • Market Cap
  • ALT 292.0M
  • GAU 408.3M
  • IPO Year
  • ALT N/A
  • GAU N/A
  • Fundamental
  • Price
  • ALT $3.83
  • GAU $2.16
  • Analyst Decision
  • ALT Strong Buy
  • GAU Strong Buy
  • Analyst Count
  • ALT 6
  • GAU 2
  • Target Price
  • ALT $17.40
  • GAU $3.00
  • AVG Volume (30 Days)
  • ALT 3.0M
  • GAU 2.7M
  • Earning Date
  • ALT 08-12-2025
  • GAU 08-13-2025
  • Dividend Yield
  • ALT N/A
  • GAU N/A
  • EPS Growth
  • ALT N/A
  • GAU N/A
  • EPS
  • ALT N/A
  • GAU N/A
  • Revenue
  • ALT $20,000.00
  • GAU $309,575,000.00
  • Revenue This Year
  • ALT N/A
  • GAU $80.61
  • Revenue Next Year
  • ALT $761,880.20
  • GAU $43.30
  • P/E Ratio
  • ALT N/A
  • GAU N/A
  • Revenue Growth
  • ALT N/A
  • GAU 223.63
  • 52 Week Low
  • ALT $2.90
  • GAU $1.00
  • 52 Week High
  • ALT $11.16
  • GAU $2.19
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • GAU 77.92
  • Support Level
  • ALT $3.35
  • GAU $2.09
  • Resistance Level
  • ALT $3.66
  • GAU $2.16
  • Average True Range (ATR)
  • ALT 0.19
  • GAU 0.10
  • MACD
  • ALT 0.07
  • GAU 0.02
  • Stochastic Oscillator
  • ALT 86.18
  • GAU 97.64

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

Share on Social Networks: